ArticleJBMR plus2020
Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study.
Article in JBMR plus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Efficacy of Osteoanabolic Agents in Type 2 Diabetes Mellitus: a Meta-analysis and Review of the Literature.Current osteoporosis reports · 2025Pooled it
- Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023Pooled it
- Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Trial
- Optimizing Bone Health in Diabetes: Strategies for Fracture Risk Reduction in Public Healthcare.Current diabetes reports · 2025Review
- Osteoporosis in Adult Patients Undergoing Spinal Reconstructive Surgery: Associated Complications and Management.Global spine journal · 2025Article
- Review
- Bone metabolism in diabetes: a clinician's guide to understanding the bone-glucose interplay.Diabetologia · 2024Review
- Bone Health in Patients With Type 2 Diabetes.Journal of the Endocrine Society · 2024Article
- Insights and implications of sexual dimorphism in osteoporosis.Bone research · 2024Review
- Article
- Efficacy of Osteoporosis Medications in Patients with Type 2 Diabetes.Current osteoporosis reports · 2024Review
- Diabetes and Osteoporosis.Indian journal of orthopaedics · 2023Review
- Effect of Antidiabetic Drugs on Bone Health in Patients with Normal Renal Function and in Chronic Kidney Disease (CKD): Insight into Clinical Challenges in the Treatment of Type 2 Diabetes.Journal of clinical medicine · 2023Review
- Antiresorptive Versus Anabolic Therapy in Managing Osteoporosis in People with Type 1 and Type 2 Diabetes.JBMR plus · 2023Review
- Reversal of the diabetic bone signature with anabolic therapies in mice.Bone research · 2023Article
- Efficacy of zoledronate, denosumab or teriparatide in postmenopausal women with type 2 diabetes mellitus at high risk of fragility fractures: protocol of an open, blinded endpoint randomized controlled pilot trial.Therapeutic advances in endocrinology and metabolism · 2023Article
- Osteoporosis and diabetes - possible links and diagnostic difficulties.Reumatologia · 2023Review
- Secondary Osteoporosis and Metabolic Bone Diseases.Journal of clinical medicine · 2022Review
- Effect of Teriparatide on Bone Mineral Density and Trabecular Bone Score in Type 2 Diabetic Patients with Osteoporosis: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2022Article
- Nmp4, a Regulator of Induced Osteoanabolism, Also Influences Insulin Secretion and Sensitivity.Calcified tissue international · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) increases fracture risk despite normal or increased BMD. Abaloparatide reduces fracture risk in patients with postmenopausal osteoporosis (PMO); however, its efficacy in women with T2DM is unknown. This post hoc analysis evaluated the efficacy and safety of abaloparatide in patients with T2DM. The analysis included patients with T2DM from the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.